Document:

Exhibit 10.7.1

 

Execution Version

 

EMPLOYMENT
AGREEMENT

 

THIS EMPLOYMENT AGREEMENT
(the “Agreement”), made effective as of March 1, 2013, is entered into by Intercept Pharmaceuticals, Inc. (the “Company”)
and Daniel Regan (“Executive”).

 

WHEREAS, the Company
desires to employ Executive, and Executive desires to be employed by the Company.

 

NOW THEREFORE, in consideration
of the mutual covenants and promises contained in this Agreement, and other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged by the parties to this Agreement, the parties agree as follows:

 

1. 
         Term of Employment. The Company hereby agrees to employ Executive, and
Executive hereby accepts employment with the Company, upon the terms set forth in this Agreement, for the period commencing
on March 4, 2013 (the “Commencement Date”) and ending on March 4, 2014, unless sooner terminated in accordance
with the provisions of Section 4 (such period, the “Initial Term”); provided, however, that on each
anniversary of the Commencement Date, the term of employment under this Agreement shall be automatically extended for an
additional one-year period (each such period, a “Subsequent Period”) unless terminated sooner pursuant to Section
4 or if, at least thirty (30) days prior to the applicable anniversary date, either Executive or the Company provides written
notice to the other party electing not to extend. The Initial Term together with each Subsequent Term, if any, are referred
to hereinafter as the “Agreement Term.”

 

2.     
     Title; Capacity. During the Agreement Term, the Company will employ Executive as its
Chief Commercial Officer to perform the duties and responsibilities inherent in such position (which shall initially include,
without limitation, those set forth in Schedule 1 to this Agreement) and such other duties and responsibilities as the Chief
Executive Officer of the Company (the “CEO”) shall from time to time reasonably assign to Executive. Within
forty-five (45) days of the Commencement Date, and on an annual basis thereafter, the Company’s Board of Directors (the
“Board”), in consultation with Executive and the CEO, will set reasonably attainable, specific goals pursuant to
the Operating Plan of the Company as in effect from time to time. Executive shall report directly to the CEO and shall be
subject to the supervision of, and shall have such authority as is delegated to Executive by, the CEO, which authority shall
be sufficient to perform his duties hereunder. Executive will work out of the Company’s office in New York. Executive
hereby accepts such employment and agrees to undertake the duties and responsibilities set out in Schedule 1. Executive shall
devote his full business time, energies and attention in the performance of the foregoing services.

 

3.       
   Compensation and Benefits.

 

3.1          Salary.
The Company shall pay Executive an initial annualized base salary of $350,000, payable in accordance with the Company’s
regular payroll practices. Such base salary shall be subject to annual review and increase (but not decrease) as may be determined
and approved by the Board or the Company’s Compensation Committee in its sole discretion. Such annual review will be completed
by March 15 in each year beginning with March 15, 2014.

 

    	 

    	 

    

 

3.2          Bonuses.
At the end of a given fiscal year, Executive will be eligible to receive a bonus equal to up to 40% of his base salary in effect
at the end of such fiscal year. The amount of any such bonus shall be based on factors including, but not limited to, Executive’s
achievement, as determined by the Board or the Company’s Compensation Committee in its sole discretion, of reasonable goals
and milestones established in advance by the Board or the Company’s Compensation Committee in consultation with the CEO and
Executive. The period for calculation of the bonus shall be consistent with the Company’s fiscal year. The goals and milestones
will be communicated to Executive within forty-five (45) days of the start of the new fiscal year, or in the case of the 2013 fiscal
year, within forty-five (45) days of the Commencement Date. Such bonus, if any, will be paid to Executive on or after January 1
and in any case no later than March 15 of the immediately succeeding fiscal year. The bonus shall be paid in cash; provided
that, if requested by Executive and if approved by the Board or the Company’s Compensation Committee in its sole discretion,
some or all of the bonus for which Executive may be eligible in that future year may be paid in options or restricted stock (valued
at the fair market value thereof), or any combination of the foregoing. For the period beginning on
the Commencement Date and ending on the last day of the 2013 fiscal year, Executive shall be eligible to receive a prorated bonus
(calculated as the annual bonus that would have been paid for the entire 2013 fiscal year multiplied by a fraction the numerator
of which is equal to the number of days Executive worked in the applicable fiscal year and the denominator of which is equal to
the total number of days in such year).

 

3.3          Stock
Options.

 

(a)          On
the Commencement Date, the Company shall award Executive a stock option under its 2012 Equity Incentive Plan (the “2012 Plan”)
to purchase 130,000 shares of the Company’s common stock at a per share exercise price equal to the closing price of the
common stock on such date (the “Option”), such price being the fair market value of one share of the Company’s
common stock on the date thereof. The Option will be evidenced in writing by a stock option agreement provided by the Company,
which agreement will specify vesting over four (4) years and exercise of vested options for up to ten (10) years, subject to Section
3.3(b) hereof and the 2012 Plan.

 

(b)          
The Option shall vest as follows: (i) one-quarter of the Option (i.e. 32,500 shares) will vest on the first anniversary of the
Commencement Date; and (ii) the remaining balance of the 97,500 shares will vest in equal quarterly installments in arrears over
the three (3) year period commencing on the first anniversary of the Commencement Date and ending on the fourth anniversary of
the Commencement Date, all subject to Executive’s continued employment by the Company and the 2012 Plan, except as otherwise
set forth herein.

 

(c)          At
the sole discretion of the Board or the Company’s Compensation Committee, additional stock options or other stock awards
may be granted to Executive from time to time.

 

    	2

    	 

    

 

3.4           Fringe
Benefits. Executive shall be entitled to participate in all bonus and benefit programs that the Company establishes and makes
available to its executives and/or employees from time to time, including, but not limited to, health care plans, dental care plans,
supplemental retirement plans, life insurance plans, disability insurance plans and incentive compensation plans, to the extent
that Executive is eligible under, and subject to the terms and conditions of, the applicable plan documents governing such programs.
The Company shall pay 100% of the premium cost for health insurance coverage for Executive, and 90% of the additional cost of coverage
for his spouse and children, provided that his spouse and dependents are not covered by an equivalent health insurance
plan provided by his spouse’s employer. Executive shall be eligible to accrue up to four (4) weeks of paid vacation each
calendar year (to be taken at such times and in such number of days as Executive shall determine in consultation with the CEO and
in a manner so as not to impair or otherwise interfere with Executive’s ability to perform his duties and responsibilities
hereunder). The vacation days for which Executive is eligible shall accrue at the rate of 1.67 days
per month that Executive is employed during such calendar year. Vacation accrual will be capped at 1.75 times Executive’s
annual vacation accrual. When Executive’s accrued vacation reaches the cap, Executive will not accrue additional vacation
time until some of the previously accrued vacation is used and the accrued amount falls below the cap, unless the Company is acquired
by another business venture, in which case none of the previous year’s accrued vacation will be subject to a cap. Executive
shall also be eligible for paid holidays and up to five (5) paid sick days annually, in accordance with the Company’s
policies for its senior executives as in effect from time to time. At the end of each calendar year, all unused sick days shall
be forfeited.

 

3.5           Relocation.
The Company shall provide reimbursement to Executive for reasonable and documented expenses, less all applicable withholdings and
deductions required by law, relating to (a) Executive’s relocation from Boston, Massachusetts to a residence within a reasonable
daily commute from New York City and (b) Executive commuting from his home in Massachusetts to New York prior to the date he relocates
to the New York City area (collectively, “Relocation Assistance”). The Relocation Assistance is conditioned on Executive’s
relocation to the New York City area in 2013. The Company will reimburse Executive for authorized and
documented eligible relocation expenses as soon as commercially practicable following the date on which Executive provides documentation
of the expense which is reasonably acceptable to the Company, but in any event no later than 60 days following the date on which
Executive submits all necessary documentation relating to such expense.

 

3.6           Reimbursement
of Expenses. The Company shall reimburse Executive for reasonable travel, entertainment and other expenses incurred or paid
by Executive in connection with, or related to the performance of his duties, responsibilities or services under this Agreement,
upon presentation by Executive of documentation, expense statements, vouchers and/or such other supporting information as the Company
may request. Executive must submit proper documentation for each such expense within sixty (60) days after the later of (i) his
incurrence of such expense or (ii) his receipt of the invoice for such expense. The Company will reimburse Executive for that expense
within thirty (30) days after receipt of the documentation.

 

3.7           Withholdings.
Payments made under this Section 3 shall be subject to applicable federal, state and local taxes and withholdings, if any.

 

4.          Termination
of Employment Period. The Agreement Term shall terminate upon the occurrence of any of the following:

 

    	3

    	 

    

 

4.1          Expiration
of the Agreement Term. This Agreement shall expire at the end of the Agreement Term; provided, that notice is given
in accordance with Section 1 of this Agreement.

 

4.2          Termination
by the Company for Cause. At the election of the Company, for Cause (as defined below), immediately following written notice
by the Company to Executive, which notice shall identify in reasonable detail the Cause upon which termination is based. For the
purposes of this Agreement, “Cause” for termination shall be deemed to exist upon:

 

(a)          a
good faith finding by the Company that (i) Executive has engaged in material dishonesty, willful misconduct, or gross negligence;
(ii) Executive has breached or has threatened to breach his Invention, Non-Disclosure, and Non-Solicitation Agreement; or (iii)
Executive has materially breached this Agreement, and Executive has failed to cure such conduct or breach within thirty (30) days
after his receipt of written notice from the Company of such breach; or

 

(b)          Executive’s
conviction, guilty plea, or entry of nolo contendere to any crime involving moral turpitude, fraud or embezzlement, or any felony.

 

4.3          Termination
By Executive for Good Reason. At the election of Executive, for Good Reason. For purposes of this Agreement, “Good Reason”
means the occurrence, without Executive’s written consent, of either of the events or circumstances set forth in clauses
(a) or (b) below. In addition, notwithstanding the occurrence of either of the events enumerated in clause (a) or (b), such occurrence
shall not be deemed to constitute Good Reason if, within thirty (30) days after the Company’s receipt of written notice from
Executive of the occurrence or existence of an event or circumstance enumerated in clauses (a) through (c), such event or circumstance
has been remedied by the Company.  Executive shall not be deemed to have terminated his employment for Good Reason unless
he first delivers a written notice of termination to the Company identifying in reasonable detail the acts or omissions constituting
Good Reason within ninety (90) days after their occurrence and the provision of this Agreement relied upon, such acts or omissions
are not cured by the Company within thirty (30) days of the receipt of such notice, and Executive actually ends his employment
within one-hundred and twenty (120) days after the Company’s failure to cure. 

 

(a)          any
other action or omission by the Company which results in a material diminution in Executive’s position, status, offices,
titles, authority, responsibilities, or reporting requirements;

 

(b)          a
change by the Company in the location at which Executive performs his principal duties for the Company to a different location
that is (i) outside a radius of fifty (50) miles from Executive’s principal residence immediately prior to the date on which
such change occurs, or (ii) more than fifty (50) miles from the location at which Executive performed his principal duties for
the Company immediately prior to the date on which such change occurs. The Executive’s residence for purposes of this Section
4.3(b) shall be the residence he establishes in the New York City area prior to the end of 2013 pursuant to Section 3.5 ; or

 

(c)          any
material breach by the Company of this Agreement.

 

    	4

    	 

    

 

4.4           Death
or Disability. Immediately upon Executive’s death or disability. As used in this Agreement, the determination of “disability”
shall occur when Executive, due to a physical or mental disability, for a period of 60 consecutive days, or 120 days in the aggregate
whether or not consecutive, during any 360-day period, is unable to perform the services contemplated under this Agreement. A determination
of disability shall be made by a physician satisfactory to both Executive and the Company; provided, that, if Executive
and the Company do not agree on a physician, Executive and the Company shall each select a physician and these two together shall
select a third physician, whose determination as to disability shall be binding on all parties.

 

4.5           Termination
by Executive Without Good Reason or Termination by the Company Without Cause. At the election of Executive without Good Reason
or by the Company without Cause, upon not less than thirty (30) days’ prior written notice to the other party.

 

5.      
    Effect of Termination.

 

5.1           Payments
Upon Termination for Any Reason. In the event Executive’s employment is terminated pursuant to Section 4, the Company
shall pay to Executive (or his estate or legal representative, if applicable), on the date of his termination of employment with
the Company, the compensation and benefits under Sections 3.1, 3.4, 3.5 and 3.6 that are accrued and unpaid through such termination
date (including, without limitation, an amount equal to all accrued but unused vacation pay and unreimbursed expenses). Subject
to Section 5.5, in the event of termination of Executive’s employment by Executive by reason of non-renewal of the Agreement
Term pursuant to Sections 1 and 4.1, the Company for Cause pursuant to Section 4.2, by reason of Executive’s death or disability
pursuant to Section 4.4, or by Executive without Good Reason pursuant to Section 4.5, Executive shall not receive any compensation
or benefits other than as expressly stated in this Section 5.1 and as otherwise required by law.

 

5.2           Termination
by the Company Without Cause, by the Company by Reason of Non-Renewal of Agreement Term, or by Executive for Good Reason. Subject
to Section 5.3 below, in addition to the payments and provisions under Section 5.1, in the event of termination of Executive’s
employment by the Company by reason of non-renewal of the Agreement Term pursuant to Sections 1 and 4.1, by Executive for Good
Reason pursuant to Section 4.3, or by the Company without Cause pursuant to Section 4.5, provided that Executive executes a release
of claims in a form reasonably satisfactory to the Company and Executive (the “Release”), which Release must be presented
to Executive on or before the date of termination and effective and irrevocable prior to the sixty (60th) day following
the termination of the Executive's employment, the Company shall provide Executive with the following:

 

(a)          six
(6) months of Executive’s base salary in effect at the time of termination of employment, payable according to the Company’s
payroll commencing on the first payroll date following the date the Release is effective and irrevocable, provided, however, that
if the sixty (60) day period in which the Release must be effective and irrevocable begins in one taxable year of the Executive
and ends in a later taxable year, the payments will commence in the later taxable year; and

 

    	5

    	 

    

 

(b)          the
Company will, for a period of six (6) months following Executive’s termination from employment, continue Executive’s
participation in the Company’s group health plan and dental plan and shall pay that portion of the premiums that the Company
paid on behalf of Executive and his dependents during Executive’s employment, provided, however, that if the
Company’s health insurance plan and/or dental plan does not permit such continued participation in such plan after Executive’s
termination of employment, then the Company shall pay that portion of the premiums associated with COBRA continuation coverage
that the Company paid on behalf of Executive and his dependents during Executive’s employment ,
including any administrative fee, on Executive’s behalf for such twelve-month period; and provided, further,
that if Executive becomes employed with another employer during the period in which continued health insurance and/or dental insurance
is being provided pursuant to this Section, the Company shall not be required to continue such health and dental benefits, or if
applicable, to pay the costs of COBRA, if Executive becomes covered under a health insurance plan of the new employer. (For purposes
of this Section 5.2(b), the term “Executive” shall include, to the extent applicable, Executive’s spouse and
any of his dependents covered under the Company’s group health plan and/or dental plan prior to his termination of employment).

 

5.3          Termination
in the Event of a Change in Control.

 

(a)          In
addition to the payments and provisions under Section 5.1 but in lieu of, and not in addition to, the payments required pursuant
to Section 5.2 above and 5.5 below, in the event Executive’s employment with the Company is terminated by the Company by
reason of non-renewal of the Agreement Term pursuant to Sections 1 and 4.1, by Executive for Good Reason pursuant to Section 4.3,
or by the Company without Cause pursuant to Section 4.5, in any such case, in anticipation of and/or within twelve (12) months
following a Change in Control (as defined below), provided that Executive (or his legal representative, if applicable) executes
timely a Release and allows it to become binding, Executive shall be entitled to the following:

 

(i)          a
lump sum cash amount equal to twelve (12) months of Executive’s base salary in effect at the time of Executive’s termination,
such payment to be made on the first payroll date following the date the Release is effective and irrevocable, provided, however,
that if the sixty (60) day period in which the Release must be effective and irrevocable begins in one taxable year of the Executive
and ends in a later taxable year, the payment will be made in the later taxable year;

 

(ii)         for
up to twelve (12) months after Executive’s date of termination, the Company shall continue Executive’s participation
in the Company’s group health and dental plan and shall pay that portion of the premiums that the Company paid on behalf
of Executive and his dependents during Executive’s employment; provided, however, that if the Company’s
health insurance plan and/or dental insurance plan does not permit Executive’s continued participation in such plan after
his termination of employment, then the Company shall pay that portion of the premiums associated with COBRA continuation coverage
that the Company paid on behalf of Executive and his dependents during Executive’s employment,
including administrative fees, on Executive’s behalf for so long as COBRA continuation coverage is available,
up to twelve (12) months; and provided, further, that if Executive becomes employed with another employer during
the period in which continued health insurance and/or dental insurance is being provided pursuant to this Section, the Company
shall not be required to continue the relevant benefits, or if applicable, to pay the relevant costs of COBRA, if Executive becomes
covered under a health insurance plan and/or dental plan of the new employer. (For purposes of this Section 5.3(a)(ii), the term
“Executive” shall include, to the extent applicable, Executive’s spouse and any of his dependents covered under
the Company’s group health plan and/or dental plan prior to his termination of employment.)

 

    	6

    	 

    

 

(b)          As
used herein, “Change in Control” shall occur or be deemed to occur if any of the following events occur:

 

(i)          any
sale, lease, exchange or other transfer (in one transaction or a series of transactions) of all or substantially all of the assets
of the Company; or

 

(ii)         any
consolidation or merger of the Company (including, without limitation, a triangular merger) where the shareholders of the Company
immediately prior to the consolidation or merger, would not, immediately after the consolidation or merger, beneficially own, directly
or indirectly, shares representing in the aggregate more than fifty percent (50%) of the combined voting power of all the outstanding
securities of the corporation issuing cash or securities in the consolidation or merger (or of its ultimate parent corporation,
if any); or

 

(iii)        a
third person, including a “person” as defined in Section 13(d)(3) of the Securities Exchange Act of 1934, as amended
(the “Exchange Act”) (but other than (x) the Company, (y) any employee benefit plan of the Company, or (z) investors
purchasing equity securities of the Company pursuant to a financing or a series of financings approved by the Board of Directors
of the Company) becomes the beneficial owner (as defined in Rule 13d-3 under the Exchange Act) directly or indirectly, of Controlling
Securities (as defined below). “Controlling Securities” shall mean securities representing 25% or more of the total
number of votes that may be cast for the election of the directors of the Company.

 

5.4          Effect
of Termination on Stock Options and Other Equity Compensation.

 

(a)          In
the event of Executive’s termination by Executive by reason of non-renewal of the Agreement Term pursuant to Sections 1 and
4.1, by the Company for Cause pursuant to Section 4.2, or by Executive without Good Reason pursuant to Section 4.5, all unvested
stock and stock options granted to Executive before and after the date of this Agreement shall be immediately forfeited upon the
effective date of such termination of employment or as otherwise provided in the option agreement; provided, that,
Executive shall have ninety (90) days from the date of termination to exercise the vested portion of any stock or stock options,
subject to Section 3.3(b) hereof and the 2012 Plan and any amendments thereto as well as any additional stock and/or stock option
plans.

 

(b)          In
the event of Executive’s termination by the Company by reason of non-renewal of the Agreement Term pursuant to Sections 1
and 4.1, by Executive for Good Reason pursuant to Section 4.3, or by the Company without Cause pursuant to Section 4.5, and provided
that Executive (or his legal representative, if applicable) executes timely a Release and allows it to become binding, that number
of Executive’s stock and stock options that would otherwise have vested from the effective date of Executive’s termination
to the first anniversary of such date shall vest as of the date of the execution of the Release and Executive (or his estate or
legal representative, if applicable) shall have one (1) year to exercise the vested portion of such stock or stock options, subject
to Section 3.3(b) hereof and the 2012 Plan and any amendments thereto as well as any additional stock and/or stock option plans.

 

    	7

    	 

    

 

(c)          In
the event Executive’s employment with the Company is terminated by the Company by reason of non-renewal of the Agreement
Term pursuant to Sections 1 and 4.1, by Executive for Good Reason pursuant to Section 4.3, or by the Company without Cause pursuant
to Section 4.5, in any such case, in anticipation of, on or within twelve (12) months following a Change in Control, in lieu of
the acceleration provided for pursuant to Section 5.4(b) above, provided that Executive (or his legal representative, if applicable)
executes timely a Release and allows it to become binding, all of Executive’s stock and stock options shall immediately become
exercisable with respect to all shares underlying such options and Executive (or his estate or legal representative, if applicable)
shall have one (1) year from the date of termination to exercise such stock and/or stock options, subject to Section 3.3(b) hereof
and the 2012 Plan and any amendments thereto as well as any additional stock and/or stock option plans.

 

(d)          In
the event Executive’s employment with the Company is terminated by reason of disability pursuant to Section 4.4, and provided
that Executive (or his legal representative, if applicable) executes timely a Release and allows it to become binding, all unvested
stock and stock options granted to Executive before and after the date of this Agreement shall be immediately forfeited upon the
effective date of such termination of employment or as otherwise provided in the option agreement; provided, that,
Executive shall have (i) one (1) year from the date of termination to exercise the vested portion of any stock or stock options
or such longer exercise period as may be provided for in the applicable stock option plan and (ii) such additional vesting rights
as may be provided for in the applicable stock option plan, subject, in each case, to Section 3.3(b) hereof and the 2012 Plan and
any amendments thereto as well as any additional stock option plans.

 

5.5           Limitation
on Benefits. The Company will make the payments under this Agreement without regard to whether the deductibility of such payments
(or any other payments or benefits) would be limited or precluded by Section 280G of the Internal Revenue Code of 1986, as amended
(the “Code”) and without regard to whether such payments would subject Executive to the federal excise tax levied on
certain “excess parachute payments” under Code Section 4999 of the Code; provided, however, that if the Total After-Tax
Payments (as defined below) would be increased by the reduction or elimination of any payment and/or other benefit (including the
vesting of the options) under this Agreement, then the amounts payable under this Agreement will be reduced or eliminated as follows,
if possible: (i) first, by reducing or eliminating the vesting of that options that occurs as a result of such Change in Control
(as provided above) and (ii) second, by reducing or eliminating any cash payments or other benefits (other than the vesting of
the options), to the extent necessary to maximize the Total After-Tax Payments. The Company’s independent, certified public
accounting firm will determine whether and to what extent payments or vesting under this agreement are required to be reduced in
accordance with the preceding sentence. For purposes of this Agreement, “Total After-Tax Payments” means the total
of all “parachute payments” (as that term is defined in Section 280G(b)(2) of the Code) made to or for the benefit
of Executive (whether made under the Agreement or otherwise), after reduction for all applicable federal taxes (including, without
limitation, the tax described in Section 4999 of the Code). The Company agrees to pay for all costs associated with the determination
of the payments or vesting required to be reduced andfor the avoidance of doubt, shall not be required to pay any taxes, penalties,
interest or other expenses to which Executive may be subject.

 

    	8

    	 

    

 

5.6           Withholdings.
Payments made under this Section 5 shall be subject to applicable federal, state and local taxes and withholdings.  If the
payment of any COBRA or health insurance premiums would otherwise violate the nondiscrimination rules or cause the reimbursement
of claims to be taxable under the Patient Protection and Affordable Care Act of 2010, together with the Health Care and Education
Reconciliation Act of 2010 (collectively, the “Act”) or Section 105(h) of the Code, the Company paid premiums shall
be treated as taxable payments and be subject to imputed income tax treatment to the extent necessary to eliminate any discriminatory
treatment or taxation under the Act or Section 105(h) of the Code. 

 

6.          Invention,
Non-Disclosure, and Non-Solicitation. As a condition of Executive’s employment, Executive shall execute the Invention,
Non-Disclosure, and Non-Solicitation Agreement attached hereto as Exhibit A.

 

7.          Notices.
All notices, requests, consents and other communications hereunder will be in writing, will be addressed, if to the Company, at
its principal corporate offices to the attention of the Legal Department, and if to Executive, at his address set forth on the
signature page hereto, or in either case, such other address as a party may designate by notice hereunder, or , in the case of
Executive, to his current home address, and will be either (i) delivered by hand, (ii) sent by overnight courier, or
(iii) sent by registered or certified mail, return receipt requested, postage prepaid. All notices, requests, consents and
other communications hereunder will be deemed to have been given either (i) if by hand, at the time of the delivery thereof
to the receiving party at the address of such party set forth above, (ii) if sent by overnight courier, on the next business
day following the day such notice is delivered to the courier service, or (iii) if sent by registered or certified mail, on the
fifth business day following the day such mailing is made.

 

8.          Absence
of Restrictions. Executive represents and warrants that he is not bound by any employment contracts, restrictive covenants
or other restrictions that prevent Executive from entering into employment with, or carrying out his responsibilities for, the
Company, or which are in any way inconsistent with any of the terms of this Agreement.

 

9.          Entire
Agreement. This Agreement constitutes the entire agreement between the parties and supersedes all prior agreements and understandings,
whether written or oral relating to the subject matter of this Agreement, with the exception of the Invention, Non-Disclosure,
and Non-Solicitation Agreement, dated as of the date hereof, by and between the Company and Executive. Notwithstanding the foregoing,
the parties to this Agreement acknowledge that stock options and other equity awards may be granted by the Company to Executive
under and pursuant to the 2012 Plan and any amendments thereto, as well as any additional plans, and the award agreements related
to such plans.

 

10.         Amendment.
This Agreement may be amended or modified only by a written instrument executed by both the Company and Executive.

 

    	9

    	 

    

 

11.         Governing
Law; Consent to Jurisdiction. This Agreement shall be construed, interpreted and enforced in accordance with the laws of the
State of New York without regard to conflict of law principles. Any action, suit or other legal proceeding arising under or relating
to any provision of this Agreement shall be commenced only in a court of the State of New York (or, if appropriate, a federal court
located within the State of New York), and the Company and Executive each consents to the jurisdiction of such a court. The Company
and Executive each hereby irrevocably waive any right to a trial by jury in any action, suit or other legal proceeding arising
under or relating to any provision of this Agreement.

 

12.         Successors
and Assigns. This Agreement shall be binding upon and inure to the benefit of both parties and their respective successors
and assigns, including any corporation with which, or into which, the Company may be merged or which may succeed to the Company’s
assets or business, provided, however, that the obligations of Executive are personal and shall not be assigned by
him. Notwithstanding the foregoing, if Executive dies the compensation and benefits stated in this Agreement will be paid to his
beneficiary or to his estate if no beneficiary.

 

13.         Miscellaneous.

 

13.1         No
Waiver. No delay or omission by the Company in exercising any right under this Agreement shall operate as a waiver of that
or any other right. A waiver or consent given on any one occasion shall be effective only in that instance and shall not be construed
as a bar or waiver of any right on any other occasion.

 

13.2         Captions.
The captions of the sections of this Agreement are for convenience of reference only and in no way define, limit or affect the
scope or substance of any section of this Agreement.

 

13.3         Severability.
In case any provision of this Agreement shall be invalid, illegal or otherwise unenforceable, the validity, legality and enforceability
of the remaining provisions shall in no way be affected or impaired thereby.

 

13.4         Counterparts.
This Agreement may be executed in two or more counterparts, each of which shall be deemed an original but all of which together
shall constitute one and the same instrument. This Agreement may be delivered by facsimile, and facsimile signatures shall be treated
as original signatures for all applicable purposes.

 

13.5         Blue
Penciling. To the extent that any provision herein or in any plan of nonqualified deferred compensation that this document
is a part of contravenes the requirements of Code Section 409A or the regulations thereunder), such provision shall be appropriately
modified in accordance with available IRS guidance (including without limitation IRS Notice 2010-6 and related guidance) so that
Executive is not subject to the adverse effects of Code Section 409A but will nevertheless retain, to the extent possible, the
economic benefit of the provision.

 

    	10

    	 

    

 

13.6         Section
409A. 

 

(a)          The
payments under this Agreement are intended either to be exempt from Section 409A of the Internal Revenue Code (“Section
409A”) under the short-term deferral, separation pay, or other applicable exception, or to otherwise comply with Section 409A.
The parties agree that this Agreement shall be administered in a manner consistent with such intent. For purposes of Section 409A,
all payments under this Agreement shall be considered separate payments. If any amount or benefit payable to the Executive under
this Agreement upon a “termination of employment” is determined by the Company to constitute a “deferral of compensation”
for purposes of Section 409A (after taking into account any applicable exceptions), such amount or benefit shall not be paid or
provided until the Executive has also experienced a “separation from service” from the Company within the meaning of
Section 409A. Notwithstanding any provision to the contrary, to the extent Executive is considered a specified employee under
Section 409A and would be entitled during the six-month period beginning on Executive’s separation from service to a payment
that is not otherwise excluded under Section 409A, such payment will not be made until the earlier of the six-month anniversary
of Employee’s separation from service or death; provided that
the first payment made after the delay shall include all amounts that would have been paid earlier
but for such six (6) month delay. At the request of the Executive, the Company shall set aside those payments that would otherwise
be made in such six-month period in a trust that is in compliance with Rev. Proc. 92-64. 

 

(b)          If
an expense reimbursement or provision of in-kind benefit provided to the Executive under this Agreement is not exempt from Section
409A of the Code, the following rules apply: (i) in no event shall any reimbursement be paid after the last day of the taxable
year following the taxable year in which the expense was incurred; (ii) the amount of reimbursable expenses incurred or provision
of in-kind benefits in one tax year shall not affect the expenses eligible for reimbursement or the provision of in-kind benefits
in any other tax year; and (iii) the right to reimbursement for expenses or provision of in-kind benefits is not subject to liquidation
or exchange for any other benefit.

 

(c)          The
parties agree to negotiate in good-faith the amendment of this Agreement, as necessary, to avoid any violations of Section 409A
in a manner that preserves the original intent of the parties to the extent reasonably possible. Notwithstanding the foregoing,
the Company makes no representations that the payments and benefits provided under this Agreement comply with Section 409A and
in no event shall the Company be liable for all or any portion of any taxes, penalties, interest or other expenses that may be
incurred by Executive on account of non-compliance with Section 409A.

 

[Remainder of Page
Intentionally Left Blank; Signature Page Follows]

 

    	11

    	 

    

 

IN WITNESS WHEREOF, the
parties hereto have executed this Agreement as of the day and year first set forth above.

 

	THE COMPANY:
	 
	INTERCEPT PHARMACEUTICALS, INC.
	 	 	 
	By:	/s/ Mark Pruzanski
	 	Name:	Mark Pruzanski, MD
	 	Title:	President and Chief Executive Officer

 

	EXECUTIVE:	 	 
	 	 	 	 
	By:	/s/ Daniel Regan	 
	 	Name:    Daniel Regan
	Address for Notice Purposes:
	 	 	 
	 	 	 
	 	 	 

 

[Employment Agreement – Daniel
Regan]

 

    	 

    	 

    

 

Schedule 1

 

		·	Work with senior management and the Board on designing and planning implementation of corporate and commercial strategy

 

		·	Work with senior management to create an integrated commercial, clinical and regulatory life cycle management strategy to maximize
value of OCA and other products and product candidates in the pipeline

 

		·	Plan, budget and build commercial capability in support of the forecast 2015 launch of OCA for PBC in the US and Europe, recruiting
world class employees and retaining consultants and vendors according to plan

 

		·	Develop US and European launch plans, including pricing and market access analyses, for OCA and generate realistic revenue
and profitability forecasts across markets

 

		·	Manage to budget and deliver revenue objectives and margin targets, ensuring accurate and timely communication of results

 

		·	Work with senior management to support investor relations, analyst days and financings, as needed

 

		·	Work with senior management to support existing strategic partnerships and to evaluate, develop and support strategic business
development, M&A and licensing opportunities

 

		·	Establish relationships with KOLs, patient advocacy groups and other key constituencies, attending industry and scientific
meetings and representing the Company

 

		·	Manage customer facing medical affairs personnel during the pre-approval period

 

		·	Manage commercial project management

 

		·	Other duties, responsibilities and/or projects reasonably assigned by the CEO and in line with the CCO positionExhibit 10.7.2

 

INVENTION, NON-DISCLOSURE, AND NON-SOLICITATION
AGREEMENT

 

This Invention, Non-Disclosure, and Non-Solicitation Agreement
is made by and between Intercept Pharmaceuticals, Inc. (the “Company”) and Daniel Regan (the “Employee”).

 

IN CONSIDERATION of the Employee's employment by the Company,
and for other good and valuable consideration, the sufficiency of which is hereby acknowledged, the Employee agrees as follows:

 

1. Condition of Employment.

 

The Employee acknowledges that her employment with the Company
is contingent upon her agreement to sign and adhere to the provisions of this Invention, Non-Disclosure, and Non-Solicitation Agreement
(the “Agreement”).

 

2. Proprietary and Confidential Information.

 

(a) The Employee agrees that all information, whether or not
in writing, of a private, secret or confidential nature concerning the Company’s business, business relationships or financial
affairs (collectively, “Proprietary Information”) is and shall be the exclusive property of the Company. By way of
illustration, but not limitation, Proprietary Information may include inventions, products, processes, methods, techniques, formulas,
compositions, compounds, projects, developments, plans (including business and marketing plans), research data, clinical data,
financial data (including sales costs, profits, pricing methods), personnel data, computer programs (including software used pursuant
to a license agreement), customer and supplier lists, and contacts at or knowledge of customers or prospective customers of the
Company. The Employee will not disclose any Proprietary Information to any person or entity other than employees of the Company
or use the same for any purposes (other than in the performance of his/her duties as an employee of the Company) without written
approval by an officer of the Company, either during or after her employment with the Company, unless and until such Proprietary
Information has become public knowledge without fault by the Employee.

 

(b) The Employee agrees that all files, documents, letters,
memoranda, reports, records, data, sketches, drawings, models, laboratory notebooks, program listings, computer equipment or devices,
computer programs or other written, photographic, or other tangible material containing Proprietary Information, whether created
by the Employee or others, which shall come into his/her custody or possession, shall be and are the exclusive property of the
Company to be used by the Employee only in the performance of his/her duties for the Company and shall not be copied or removed
from the Company premises except in the pursuit of the business of the Company. All such materials or copies thereof and all tangible
property of the Company in the custody or possession of the Employee shall be delivered to the Company, upon the earlier of (i)
a request by the Company or (ii) termination of his/her employment. After such delivery, the Employee shall not retain any such
materials or copies thereof or any such tangible property.

 

    	 

    	 

    

 

(c) The Employee agrees that her obligation not to disclose
or to use information and materials of the types set forth in paragraphs (a) and (b) above, and her obligation to return materials
and tangible property set forth in paragraph (b) above also extends to such types of information, materials and tangible property
of customers of the Company or suppliers to the Company or other third parties who may have disclosed or entrusted the same to
the Company or to the Employee.

 

3. Inventions.

 

(a) The Employee will make full and prompt disclosure to the
Company of all inventions, creations, improvements, discoveries, trade secrets, secret processes, technology, know-how, methods,
developments, software, and works of authorship or other creative works, whether patentable or not, which are created, made, conceived
or reduced to practice by the Employee or under the Employee's direction or jointly with others during her employment by the Company,
whether or not during normal working hours or on the premises of the Company (all of which are collectively referred to in this
Agreement as “Inventions”).

 

(b) The Employee agrees to assign
and does hereby assign to the Company (or any person or entity designated by the Company) all her right, title and interest in
and to all Inventions and all related patents, patent applications, copyrights and copyright applications to the maximum extent
permitted by the laws of the State of New York or any like statute of any other state. The
Employee hereby also waives all claims to moral rights in any Inventions. The Employee understands that the provisions of this
Agreement requiring assignment of Inventions to the Company do not apply to any invention which qualifies fully under the provisions
of the laws of the State of New York. The Employee agrees to advise the Company promptly in
writing of any inventions that she believes meets the criteria in the laws of the State of New York.

 

(c) The Employee agrees to cooperate fully with the Company
and to take such further actions as may be necessary or desirable, both during and after her employment with the Company, with
respect to the procurement, maintenance and enforcement of copyrights, patents and other intellectual property rights (both in
the United States and foreign countries) relating to Inventions. The Employee shall sign all papers, including, without limitation,
copyright applications, patent applications, declarations, oaths, formal assignments, assignments of priority rights, and powers
of attorney, which the Company may deem necessary or desirable in order to protect its rights and interests in any Invention.
The Employee further agrees that if the Company is unable, after reasonable effort, to secure the signature of the Employee on
any such papers, any executive officer of the Company shall be entitled to execute any such papers as the agent and the attorney-in-fact
of the Employee, and the Employee hereby irrevocably designates and appoints each executive officer of the Company as her agent
and attorney-infact to execute any such papers on her behalf, and to take any and all actions as the Company may deem necessary
or desirable in order to protect its rights and interests in any Invention, under the conditions described in this sentence.

 

    	 

    	 

    

 

4. Non-Solicitation.

 

(a) While employed by the Company and for a period of one (1)
year after the termination or cessation of Employee’s employment for any reason, the Employee will not, directly or indirectly,
either alone or in association with others, recruit or solicit any person who was employed by the Company or engaged as an independent
contractor at any time during the period of the Employee's employment with the Company, except for an individual whose employment
with or service for the Company has been terminated for a period of six months or longer.

 

(b) If any restriction set forth in this Section 4 is found
by any court of competent jurisdiction to be unenforceable because it extends for too long a period of time or over too great a
range of activities or in too broad a geographic area, it shall be interpreted to extend only over the maximum period of time,
range of activities or geographic area as to which it may be enforceable.

 

(c) The geographic scope of this Section shall extend to anywhere
the Company or any of its subsidiaries is doing business, has done business or has plans to do business.

 

(d) If the Employee violates the provisions of this Section,
the Employee shall continue to be held by the restrictions set forth in this Section, until a period equal to the period of restriction
has expired without any violation.

 

5. Other Agreements.

 

The Employee hereby represents that, except as the Employee
has disclosed in writing to the Company, the Employee is not bound by the terms of any agreement with any previous employer or
other party to refrain from using or disclosing any trade secret or confidential or proprietary information in the course of his/her
employment with the Company, to refrain from competing, directly or indirectly, with the business of such previous employer or
any other party, or to refrain from soliciting employees, customers or suppliers of such previous employer or other party. The
Employee further represents that his/her performance of all the terms of this Agreement and the performance of her duties as an
employee of the Company do not and will not breach any agreement with any prior employer or other party to which the Employee is
a party (including without limitation any non-disclosure or non-competition agreement), and that the Employee will not disclose
to the Company or induce the Company to use any confidential or proprietary information or material belonging to any previous employer
or others.

 

6. United States Government Obligations.

 

The Employee acknowledges that the Company from time to time
may have agreements with other persons or with the United States Government, or agencies thereof, which impose obligations or restrictions
on the Company regarding inventions made during the course of work under such agreements or regarding the confidential nature of
such work. The Employee agrees to be bound by all such obligations and restrictions that are made known to the Employee and to
take all action necessary to discharge the obligations of the Company under such agreements.

 

    	 

    	 

    

 

7. Not An Employment Contract.

 

The Employee acknowledges that this Agreement does not constitute
a contract of employment, either express or implied, and does not imply that the Company will continue the Employee’s employment
for any period of time.

 

8. General Provisions.

 

(a) No Conflict. The Employee represents that
the execution and performance by him/her of this Agreement does not and will not conflict with or breach the terms of any other
agreement by which the Employee is bound.

 

(b) Entire Agreement. This Agreement supersedes
all prior agreements, written or oral, between the Employee and the Company relating to the subject matter of this Agreement. This
Agreement may not be modified, changed or discharged in whole or in part, except by an agreement in writing signed by the Employee
and the Company. The Employee agrees that any change or changes in his/her duties, salary or compensation after the signing of
this Agreement shall not affect the validity or scope of this Agreement.

 

(c) Severability. The invalidity or unenforceability
of any provision of this Agreement shall not affect or impair the validity or enforceability of any other provision of this Agreement.

 

(d) Waiver. No delay or omission by the Company
in exercising any right under this Agreement will operate as a waiver of that or any other right. A waiver or consent given by
the Company on any one occasion is effective only in that instance and will not be construed as a bar to or waiver of any right
on any other occasion.

 

(e) Employee Acknowledgment and Equitable Remedies.
The Employee acknowledges that the restrictions contained in this Agreement are necessary for the protection of the business and
goodwill of the Company and are considered by the Employee to be reasonable for such purpose. The Employee agrees that any breach
of this Agreement is likely to cause the Company substantial and irrevocable damage and therefore, in the event of any breach
or threatened breach of this Agreement, the Employee agrees that the Company, in addition to such other remedies that may be available,
shall be entitled to specific performance and other injunctive relief without posting a bond, and the Employee hereby waives the
adequacy of a remedy at law as a defense to such relief.

 

(f) Successors and Assigns. This Agreement
shall be binding upon and inure to the benefit of both parties and their respective successors and assigns, including any corporation
or entity with which or into which the Company may be merged or which may succeed to all or substantially all of its assets or
business, provided however that the obligations of the Employee are personal and shall not be assigned by the Employee.

 

    	 

    	 

    

 

(g) Subsidiaries and Affiliates. The Employee
expressly consents to be bound by the provisions of this Agreement for the benefit of the Company or any subsidiary or affiliate
thereof to whose employ the Employee may be transferred without the necessity that this Agreement be re-signed at the time of
such transfer.

 

(h) Governing Law, Forum and Jurisdiction.
This Agreement shall be governed by and construed as a sealed instrument under and in accordance with the laws of the State of
New York without regard to conflict of laws provisions. Any action, suit, or other legal proceeding which is commenced to resolve
any matter arising under or relating to any provision of this Agreement shall be commenced only in a court of the State of New
York (or, if appropriate, a federal court located within New York), and the Company and the Employee each consents to the jurisdiction
of such a court.

 

(i) Captions. The captions of the sections
of this Agreement are for convenience of reference only and in no way define, limit or affect the scope or substance of any section
of this Agreement.

 

    	 

    	 

    

 

THE EMPLOYEE ACKNOWLEDGES THAT HE/SHE HAS CAREFULLY READ THIS
AGREEMENT AND UNDERSTANDS AND AGREES TO ALL OF THE PROVISIONS IN THIS AGREEMENT.

 

WITNESS our hands and seals:

 

INTERCEPT PHARMACEUTICALS, INC.

 

	/s/ Mark Pruzanski	 	3/4/2013	 
	By: Mark Pruzanski, M.D.	 	Date	 
	 	 	 	 
	/s/ Daniel Regan	 	3/4/2013	 
	By: Daniel Regan	 	Date 	 

 

    	 

    	 

    

 

Exhibit A LIST OF PRIOR INVENTIONS AND ORIGINAL WORKS
OF AUTHORSHIP: Title Date Identifying Number or Brief Description 

 

	 	No inventions or improvements 
	 	 
	 	Additional Sheets Attached 
	 	 
	Signature of Employee:  	/s/ Daniel Regan
	 	 
	Printed Name of Employee: 	Daniel Regan
	 	 
	Date: 	3/4/2013

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00215-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00215-of-00352.parquet"}]]